A circadian and app-based personalized lighting intervention for the reduction of cancer-related fatigue

Authors: Mayer, Caleb ^{1, 2}, Walch, Olivia ^{3, 4}, Dempsey, Walter ^{5, 6, 7}, Hannay, Kevin ^{1, 3}, Clingan, Caroline ⁸, Bowen, Zoe ⁸, Rozwadowski, Michelle ⁸, Reichert, Zachery R. ^{9, 10}, Henry, N. Lynn ^{9, 10}, Alumkal, Joshi J. ^{9, 10}, Tewari, Muneesh ^{9, 10, 11, 12}, Forger, Daniel B. ^{1, 13, 14}, Choi, Sung Won ^{8, 10, 15, ∗}

Source: In Cell Reports Medicine 18 March 2025 6(3)

Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics

Authors: Niu, Zeqi, Kozminsky, Molly, Day, Kathleen C., Broses, Luke J., Henderson, Marian L., Patsalis, Christopher, Tagett, Rebecca, Qin, Zhaoping, Blumberg, Sarah, Reichert, Zachery R., Merajver, Sofia D., Udager, Aaron M., Palmbos, Phillip L., Nagrath, Sunitha, Day, Mark L.

Source: In Neoplasia November 2024 57

Extragonadal germ cell tumors: A clinicopathologic study with emphasis on molecular features, clinical outcomes and associated secondary malignancies

Authors: Abdulfatah, Eman, Brown, Noah A., Davenport, Matthew S., Reichert, Zachery R., Camelo-Piragua, Sandra, Heider, Amer, Huang, Tao, Vaishampayan, Ulka N., Skala, Stephanie L., Montgomery, Jeffrey S., Chinnaiyan, Arul M., Kaffenberger, Samuel D., Bawa, Pushpinder, Shao, Lina, Mehra, Rohit

Source: In Human Pathology June 2024 148:41-50

A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer

Authors: Tsung, Irene, Green, Edward, Palmbos, Phillip, Sloan, Zachery, Reichert, Zachery R., Vaishampayan, Ulka, Smith, David C., Caram, Megan E. V., Yentz, Sarah, Daignault-Newton, Stephanie, Hurley, Laura, Nguyen, Charles B., Kraft, Shawna, Alva, Ajjai

Source: Journal of urology. 209(1):121-130

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100178924241.0x000001&indx=1&recIds=ETOCvdc_100178924241.0x000001

Metastatic prostate cancer diagnosed by fine‐needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates

Authors: Cantley, Richard L., Wang, Xiaoming, Reichert, Zachery R., Chinnaiyan, Arul M., Mannan, Rahul, Cao, Xuhong, Spratt, Daniel E., Vaishampayan, Ulka N., Alumkal, Joshi J., Morgan, Todd M., Palapattu, Ganesh, Davenport, Matthew S., Pantanowitz, Liron, Mehra, Rohit

Source: Cancer cytopathology. 131(2):117-135

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100174771668.0x000001&indx=1&recIds=ETOCvdc_100174771668.0x000001

Satisfaction With Clinician-Led Germline Genetic Counseling in Patients With Prostate Cancer

Authors: Abusamra, Sophia M., Solorzano, Marissa A., Luke, Mallory, Quarles, Jake, Jacobs, Michelle F., Das, Sanjay, Kasputis, Amy, Okoth, Linda A., Patel, Milan, Seymore, Mariana, Caram, Megan E. V., Dunn, Rodney L., Merajver, Sofia D., Stoffel, Elena M., Reichert, Zachery R., Morgan, Todd M.

Source: Journal of urology. 208(5):1007-1017

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183181294.0x000001&indx=1&recIds=ETOCvdc_100183181294.0x000001

Androgen suppression with abiraterone acetate, leuprolide, PARP inhibition, and stereotactic body radiotherapy (ASCLEPIuS) in high-risk and node positive prostate cancer (PCa): Phase I multicenter results.

Authors: Jackson, William C., Dess, Robert Timothy, Jia, Angela Y, Nagar, Himanshu, Desai, Neil B, Hannan, Raquibul, Hearn, Jason W.D., Reichert, Zachery R, Marciscano, Ariel E., Davis, Brian, Zuhour, Raed, Zaorsky, Nicholas G, Garcia, Jorge A., Barata, Pedro C., Brown, Jason Robert, Mendiratta, Prateek, Feng, Felix Y, Chinnaiyan, Arul, Suresh, Krithika, Spratt, Daniel Eidelberg

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p387-387, 125p

Carcinoma of prostate sequencing of tumor and clinical endpoints (CAPSTONE): Clinical implications of recurrent genomic alterations in lethal prostate cancer.

Authors: Rebernick, Ryan, Hammer, Liat, McFarlane, Matthew, Westbrook, Thomas Christopher, Hazime, Munna, Hammoud, Tanya, Chiu, Pin-en, Owens, Xavier, Wu, Yi-Mi, Robinson, Dan R., Spratt, Daniel, Alva, Ajjai Shivaram, Jackson, William C., Reichert, Zachery R, Alumkal, Joshi J., Chinnaiyan, Arul, Cieslik, Marcin, Dess, Robert Timothy

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p220-220, 288p

Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing.

Authors: Abusamra, Sophia M., Solorzano, Marissa A., Quarles, Jake, Luke, Mallory, Patel, Milan, Vince Jr, Randy, Jiang, Ralph, Volin, Joshua, Jacobs, Michelle F., Kaffenberger, Samuel D., Salami, Simpa S., Palmbos, Phillip, Caram, Megan E. V., Hollenbeck, Brent K., Palapattu, Ganesh S., Merajver, Sofia D., Stoffel, Elena M., Hafron, Jason, Morgan, Todd M., Reichert, Zachery R.

Source: Urology Practice; Jan2025, Vol. 12 Issue 1, p63-72, 10p

Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis

Authors: Gharzai, Laila A, Jiang, Ralph, Wallington, David, Jones, Gavin, Birer, Samuel, Jairath, Neil, Jaworski, Elizabeth M, McFarlane, Matthew R, Mahal, Brandon A, Nguyen, Paul L, Sandler, Howard, Morgan, Todd M, Reichert, Zachery R, Alumkal, Joshi J, Mehra, Rohit, Kishan, Amar U, Fizazi, Karim, Halabi, Susan, Schaeffer, Edward M, Feng, Felix Y, Elliott, David, Dess, Robert T, Jackson, William C, Schipper, Matthew J, Spratt, Daniel E ^*

Source: In The Lancet Oncology March 2021 22(3):402-410

Clinically Lymph Node Positive Prostate Cancer: At the Intersection of Focal and Systemic Disease Control

Authors: Reichert, Zachery R., Dess, Robert T.

Source: Cancer journal. 26(1):53-57

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100097161239.0x000001&indx=1&recIds=ETOCvdc_100097161239.0x000001

Prostate Cancer National Summit's Call to Action

Authors: Heath, Elisabeth I., Nanus, David M., Slovin, Susan, Strand, Chuck, Higano, Celestia, Simons, Virgil H., Johnson, Crawford, Kyriakopoulos, Christos E., Reichert, Zachery R., Lory, Shannon, George, Daniel J., Mucci, Lorelei A., Marcus, Jack David, Trendel, Jill A., Bock, Cathryn H.

Source: Clinical genitourinary cancer. 17(3):161-168

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100082831334.0x000001&indx=1&recIds=ETOCvdc_100082831334.0x000001

Survival by first‐line therapy and prognostic group among men with metastatic castration‐resistant prostate cancer.

Authors: Caram, Megan E. V., Kumbier, Kyle, Tsao, Phoebe A., Burns, Jennifer, Sparks, Jordan B., Stensland, Kristian D., Reichert, Zachery R., Alumkal, Joshi J., Hollenbeck, Brent K., Shahinian, Vahakn, Tsodikov, Alexander, Skolarus, Ted A.

Source: Cancer Medicine; Jun2024, Vol. 13 Issue 12, p1-12, 12p

Subject Terms: CASTRATION-resistant prostate cancer, MEDICAL care, GROUP psychotherapy, PROSTATE-specific antigen, PROGRESSION-free survival, OVERALL survival

Translation of Targeted Radiation Sensitizers into Clinical Trials

Authors: Reichert, Zachery R. ^*, Wahl, Daniel R., Morgan, Meredith A.

Source: In Seminars in Radiation Oncology October 2016 26(4):261-270

AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.

Authors: Apolo, Andrea B., Ballman, Karla V., Sonpavde, Guru P., Berg, Stephanie A., Kim, William Y., Parikh, Rahul Atul, Teo, Min Yuen, Sweis, Randy F., Geynisman, Daniel M., Grivas, Petros, Chatta, Gurkamal S., Reichert, Zachery R, Kim, Joseph W., Bilen, Mehmet Asim, McGregor, Bradley Alexander, Srinivas, Sandy, Halabi, Susan, Perez Burbano, Gabriela, Morris, Michael J., Rosenberg, Jonathan E.

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pLBA531-LBA531, 6p

Muscadine grape skin extract in men with biochemically recurrent prostate cancer: A phase III, randomized, multicenter, placebo-controlled clinical trial.

Authors: Mandl, Adel, Zahurak, Marianna, Sfanos, Karen, Metri, Nicole, Maughan, Benjamin L., Taplin, Mary-Ellen, Shore, Neal D., McKay, Rana R., Reichert, Zachery R, Szmulewitz, Russell Zelig, Kessler, Elizabeth R., Heath, Elisabeth I., Dreicer, Robert, Stein, Cy Aaron, Marshall, Catherine Handy, Markowski, Mark Christopher, Denmeade, Samuel R., Antonarakis, Emmanuel S., Carducci, Michael Anthony, Paller, Channing Judith

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p329-329, 97p

BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).

Authors: Hussain, Maha H. A., Kocherginsky, Masha, Agarwal, Neeraj, Adra, Nabil, Zhang, Jingsong, Paller, Channing Judith, Picus, Joel, Reichert, Zachery R, Szmulewitz, Russell Zelig, Tagawa, Scott T., Kuzel, Timothy, Bazzi, Latifa, Daignault-Newton, Stephanie, Whang, Young E., Dreicer, Robert, Stephenson, Ryan D., Rettig, Matthew, Shevrin, Daniel, Chinnaiyan, Arul, Antonarakis, Emmanuel S.

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p19-19, 235p

First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Authors: Rathkopf, Dana E., Patel, Manish R., Choudhury, Atish Dipankar, Rasco, Drew W., Lakhani, Nehal J., Hawley, Jessica E., Aparicio, Ana, Narayan, Vivek, Srinivas, Sandy, Runcie, Karie, Emamekhoo, Hamid, Reichert, Zachery R, Carducci, Michael Anthony, Wells, Amber L., Liu, Can, Kandimalla, Raju, Wu, Jiaju, Nguyen, Marie Huong, Pourdehnad, Michael, Armstrong, Andrew J.

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p134-134, 235p

Reply by Authors

Authors: Abusamra, Sophia M., Solorzano, Marissa A., Luke, Mallory, Quarles, Jake, Jacobs, Michelle F., Das, Sanjay, Kasputis, Amy, Okoth, Linda A., Patel, Milan, Seymore, Mariana, Caram, Megan E. V., Dunn, Rodney L., Merajver, Sofia D., Stoffel, Elena M., Reichert, Zachery R., Morgan, Todd M.

Source: Journal of urology. 208(5):1016-1017

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183181301.0x000001&indx=1&recIds=ETOCvdc_100183181301.0x000001

Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer

Authors: Reichert, Zachery R., Hussain, Maha

Source: cancer journal. 22(5):326-329

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100036120841.0x000001&indx=1&recIds=ETOCvdc_100036120841.0x000001